Empagliflozin

Generic Name
Empagliflozin
Brand Names
Glyxambi, Jardiance, Synjardy, Trijardy
Drug Type
Small Molecule
Chemical Formula
C23H27ClO7
CAS Number
864070-44-0
Unique Ingredient Identifier
HDC1R2M35U
Background

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...

Indication

Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...

Associated Conditions
Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
Monotherapy
Clinical Trials
Related News

A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure

Phase 3
Recruiting
Conditions
Heart Failure
Interventions
Drug: BI 690517
Drug: Empagliflozin
Drug: Placebo
First Posted Date
2024-05-22
Last Posted Date
2024-12-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6000
Registration Number
NCT06424288
Locations
🇺🇸

Butler Health System Cardiovascular Consultants, Butler, Pennsylvania, United States

🇺🇸

Sentara Norfolk General Hospital, Norfolk, Virginia, United States

🇺🇸

University of California Irvine, Orange, California, United States

and more 14 locations

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Phase 1
Not yet recruiting
Conditions
Healthy Volunteers
Interventions
Drug: HD-P023
Drug: Teneligliptin
Drug: Empagliflozin
First Posted Date
2024-04-01
Last Posted Date
2024-04-02
Lead Sponsor
Handok Inc.
Target Recruit Count
40
Registration Number
NCT06339788

EMPagliflozin After Aortic Valve Replacement

Phase 4
Recruiting
Conditions
Aortic Valve Stenosis
Interventions
Drug: Placebo
Drug: Empagliflozin
First Posted Date
2023-12-15
Last Posted Date
2024-11-15
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
205
Registration Number
NCT06171802
Locations
🇩🇰

University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

First Posted Date
2023-11-29
Last Posted Date
2024-02-06
Lead Sponsor
Amir Moheet
Target Recruit Count
15
Registration Number
NCT06149793
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

First Posted Date
2023-10-16
Last Posted Date
2024-02-26
Lead Sponsor
Novo Nordisk A/S
Registration Number
NCT06083675
Locations
🇹🇭

Songklanagarind Hospital, Songkla, Thailand

🇬🇷

General Hospital of Thessaloniki "G.Papanikolaou", Thessaloniki, Greece

🇵🇱

ETG Siedlce, Siedlce, Masovian, Poland

and more 97 locations

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Phase 3
Recruiting
Conditions
Heart Failure
Interventions
Drug: Finerenone
Drug: Empagliflozin
First Posted Date
2023-09-06
Last Posted Date
2024-07-22
Lead Sponsor
Colorado Prevention Center
Target Recruit Count
1500
Registration Number
NCT06024746
Locations
🇺🇸

Kansas City, MO Investigative Site, Kansas City, Missouri, United States

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

Phase 4
Recruiting
Conditions
Type 1 Diabetes
Interventions
Drug: Empagliflozin
Drug: Placebo
First Posted Date
2023-09-01
Last Posted Date
2024-08-09
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Target Recruit Count
46
Registration Number
NCT06021145
Locations
🇨🇦

McGill University Health Centre, Montreal, Quebec, Canada

Empagliflozin Treatment in Kidney Transplant Recipients

Phase 4
Recruiting
Conditions
Type 2 Diabetes
Kidney Transplant
Interventions
Drug: Empagliflozin
First Posted Date
2023-08-28
Last Posted Date
2024-05-16
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
264
Registration Number
NCT06013865
Locations
🇺🇸

Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States

🇺🇸

Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska, United States

🇺🇸

Iowa City VA Health Care System, Iowa City, IA, Iowa City, Iowa, United States

and more 1 locations

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Phase 2
Recruiting
Conditions
Glycogen Storage Disease Type IB
Interventions
Drug: Empagliflozin
First Posted Date
2023-07-27
Last Posted Date
2023-07-27
Lead Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
10
Registration Number
NCT05960617
Locations
🇨🇳

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

First Posted Date
2023-07-14
Last Posted Date
2023-07-14
Lead Sponsor
National and Kapodistrian University of Athens
Target Recruit Count
78
Registration Number
NCT05946148
Locations
🇬🇷

"Hippocration" General Hospital of Athens, Athens, Attiki, Greece

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy